X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Efti is exclusively licensed to EOC for the territory of Greater China. EOC has full responsibility for the development and commercialisation of efti in the territory, and Immutep is eligible to receive development-based milestone payments and sales-based royalties.
Lead Product(s): Eftilagimod Alpha,Paclitaxel
Therapeutic Area: Oncology Product Name: EOC202
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: Immutep
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 31, 2021
Details:
Under the terms of the agreement, EOC Pharma will obtain exclusive rights to develop and commercialize ABI-009 in Greater China.
Lead Product(s): Nab-sirolimus
Therapeutic Area: Oncology Product Name: Fyarro
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Aadi Bioscience
Deal Size: $271.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration January 11, 2021
Details:
EOC Pharma trial will be a randomised, double-blind, placebo controlled phase II clinical study to evaluate its lead product candidate eftilagimod alpha in combination with paclitaxel in HER2-/HR+ metastatic breast cancer patients who have progression after endocrine therapy.
Lead Product(s): Eftilagimod Alpha,Paclitaxel
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Immutep
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 10, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
